Feeds:
Posts
Comments

Archive for September, 2009

TODAY’S NEWS

Novartis’ new MS drug (FTY 720) looking good in Phase III trials. New results just released.

Vertextakeover target? For a company looking to expand into Hepatitis C, Vertex is a prime candidate.

Boston Scientific and J&J making peace with the lawyer-enriching stent suits.

RECOMMENDED

Call center/phone rep training. The Impactiviti Partner Network has great providers to help you with this need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Careful of those press releases, pharma execs. They could land you in jail! Of course, mishandling data can get you publicly fired. And, from bNet Pharma, the 10 weirdest drug stories of the month.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

There’s a huge amount of stuff going on in pharma social media this month. Here’s a distillation of news and resources for your perusal:

> Google’s Sidewiki – now users can leave comments on any site (including yours). Game-changer? Annoyance? What do you think?

> Slideshow – Pharma’s Top 10 Efforts in Social Media

> An interview I gave last week (archived here) on Pharma and Social Media, via BlogTalkRadio. Good for intro’ing your colleagues to the basics, and an encouragement to move forward with low-risk strategies.

> Where are the doctors hanging out? Healthcare Professionals Social Networks (globally) (slideshow). Plus, Sermo Panels Express – you can immediately tap into physician focus groups with this service.

> Prepping for the FDA public forum on Social Media/Web 2.0 in pharma – a series of interesting posts and survey results (ongoing) over at John Mack’s blog.

> 8 Tips to help you own YouTube search results. From Jon Richman‘s Dose of Digital blog. And, from Ogilvy PR, 10 Rules of Using YouTube for Pharma and Healthcare Marketing

> From last week’s PharmaMed conference. A summary by Ellen Hoenig. An iPhone experiment that worked (ever wondered what I look like “live”? – here’s your chance!). The collected Twitterstream for the conference (via CoverItLive).

Craig DeLarge: Reflections on Pharma New Media Adoption. Timely and timeless thoughts.

Coming up in October:

DigitalPharma

Oct. 19-21 - eXL’s Digital Pharma conference, Bridgewater, NJ. This event will be quite progressive, with more of an informal “unconference” format to maximize interaction. I’ll be co-leading a pre-conference workshop on the 19th on social media, and live-blogging/Twittering. Here’s a discount code for 15% your registration: P615WOO

PLUS – My fall conference schedule (updated)

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

SocialRx – page with resources and links for pharma professionals interested in social media (plus free e-book!)

PharmaCentral – a portal for easily viewing what’s new with pharma blogs and news.

Connect with Steve Woodruff

Read Full Post »

Where to get your overview of Social Media in Pharma? Right here: http://bit.ly/socialrx

TODAY’S NEWS

Pharma’s new hot properties - vaccines.

Boehringer Ingelheim pressing forward with its experimental DPP-4 inhibitor for diabetes – Boehringer Ingelheim Pharmaceuticals, Inc. today announced the conclusion of the linagliptin pivotal Phase III clinical trials, including more than 4,000 patients in 40 countries worldwide. Phase II data for linagliptin were presented earlier this year at the annual American Diabetes Association (ADA) Scientific Sessions. Full results from the Phase III trials will be presented at international scientific congresses in 2010 and beyond...more

Merck’s diabetes drug Januvia significantly lowers blood sugar – A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia®’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two yearsmore

RECOMMENDED

Product/Launch training. The Impactiviti Partner Network has great providers to help you develop your new product training – print, on-line, and live. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Has the game changed in a dramatic way in pharma social media? I think it may be likely – my initial thoughts on Google’s Sidewiki tool, which allows user commentary on ANY site.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Take a look at the screen shot below, from Pfizer’s homepage. Believe it or not, I, or anyone else, can now leave comments “on” any website (such as Pfizer.com) using a new tool (currently in beta) from Google, called Sidewiki.

PfizerSidewiki2

Game-changer? You bet.

While the use of Google’s Sidewiki has ramifications across the entire web, for every type of site or industry, I’m going to focus here on the pharma industry. Because in pharma, it’s all about controlled messaging via corporate sites, and by and large, the idea of people being able to freely comment on (just about) anything is anathema.

The locus of control has just shifted. You can turn off comments on websites and blogs, but now, people can have their say, and the comments are accessible right there via Sidewiki when people come to your site.

How does this work? Google is not the first to try to allow user-generated commentary on any site, but they are certainly the biggest and most sophisticated. All you have to do is have a Google account, download the Google toolbar for your browser (currently IE and Firefox), and activate the Sidewiki capability. That’s it. More detailed explanations of how it works and how to get started are here and here.

MackSidewiki2

I decided to go to fellow blogger John Mack’s site and leave a Sidewiki comment there (above). Now John allows (and welcomes) comments, of course, but with Sidewiki, that is irrelevant. And even for those sites where comments are reviewed before approval, Sidewiki allows commentary completely apart from the intervention or approval of the site owner.

How will this change the game with regulatory issues? Well, it’s a big monkey wrench. A pharmaceutical company already cannot control what people say about it, or its products, on various sites. But now people can express themselves with annotations that are, in essence, sidebarred on company sites! Can a company be held liable for, say, off-label discussions that happen on Sidewiki in association with a product site?

It’s a good thing that the FDA will hold hearings in November about the use of social media/Web 2.0 in pharma communications, because we now have a new issue to put on the table. How does industry and its regulatory bodies view user-generated content that cannot be controlled, yet exists in conjunction with company-sponsored sites?

Some question whether the adoption rate of Sidewiki will be significant enough to make a huge difference. It’s a fair question, but I don’t believe that’s the point. The really important thing is: the wall has been breached. I’m not sure there’s going to be any going back as this kind of (pretty much inevitable) approach evolves – it’s a Pandora’s box.

The rules of the game just changed again. There’s going to be a lot of mixed feelings about this one…

UPDATE: Fellow industry blogger Phil Baumann was thinking about the same theme today! Read his valuable thoughts. And Wendy Blackburn chimes in with some good input on what pharma can or cannot do about Sidewiki.

Want more on Pharma Social Media? Here’s the end-of-the-month roundup.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Now Available – Archived interview on Social Media in Pharma last Friday with Paul Chaney – feel free to forward the link (http://bit.ly/29kAoN) to your colleagues.

TODAY’S NEWS

Abbott wins the bidding for Solvay’s drug unit - Abbott Laboratories will announce today the €5bn ($7.3bn) acquisition of Solvay’s pharmaceutical company, bringing a five-month takeover battle to an end and highlighting continued consolidation in the industry. The US drugmaker beat UCB of Belgium and Nycomed of Switzerland to buy the division, which is valued at between €4.5bn and €5bnmore

The Medicines Company gets encouraging results from Angiomax study – The Medicines Company today announced the presentation of 2-year clinical results from the landmark HORIZONS-AMI Trial. The trial showed that patients who had suffered the most severe form of heart attack were significantly less likely to suffer cardiac death and had better overall survival if treated with Angiomax® (bivalirudin) while undergoing angioplasty compared with those treated with heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) during angioplasty...more

Merck‘s diabetes drug Januvia with pancreatitis link? Merck says no, but FDA concerned.

RECOMMENDED

Social Media Strategy. We do that. If your company is wrestling with how to move forward with social media, contact us (stevew at impactiviti dot com, or phone at 973-947-7429) to talk.

PLUS

Is the Apple iPhone 3GS good enough to record the video of an entire conference presentation? Well, yes, it kinda can. Here are the results of my little experiment, from last week’s PharmaMed conference.

Coming up next month:

DigitalPharma

Oct. 19-21 - eXL’s Digital Pharma conference, Bridgewater, NJ. This event will be quite progressive, with more of an informal “unconference” format to maximize interaction. I’ll be co-leading a pre-conference workshop on the 19th on social media, and live-blogging/Twittering. Here’s a discount code for 15% your registration: P615WOO

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Tune in TODAY – I’ll be doing a live on-line interview on Social Media in Pharma with Paul Chaney – starts at 1 pm EST (just use the call-in number – see the link). Also, here’s a page on my site with all sorts of social media resources for pharma professionals: http://bit.ly/socialrx

TODAY’S NEWS

AstraZeneca’s new Plavix-competitor Brilinta expected to go big - It is the first antiplatelet drug to demonstrate it can reduce cardiovascular (CV) deaths compared to the current gold standard treatment, Plavix (clopidogrel) in patients with acute coronary syndromes (ACS). Results of the 18600 patient Phase III PLATO trial comparing the two drugs, were revealed at the recent European Society of Cardiology (ESC) Congress in Barcelona…Platelet expert Dr Victor Serebruany agreed the mortality data is ”marvelous,” with 107 extra lives saved compared to Plavix. “It has never been seen before and no one expected it,” he saidmore

Big oncology news (approval for new lymphoma drug) today – Allos Therapeutics Inc. said Friday that regulators approved its injectable drug Folotyn as a treatment for peripheral T-cell lymphoma, a group of rare, agressive blood cancers, sending its shares soaring. Allos said the Food and Drug Administration granted accelerated approval, allowing the company to market Folotyn for use in patients whose cancer has returned or not responded to previous treatment. Allos expects to begin selling the drug in October. There are no drugs on the market that treat peripheral T-cell lymphoma, Allos saidmore Plus, some future hope from Roche on melanoma?

So the FDA is finally going to start wresting with social media in pharma! Here’s what companies need to do to prepare for the hearing this fall. And here also.

This bothers me.

RECOMMENDED

Compliance training. When y0u need compliance training development partners for your employees, we’ve got g. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

An interview with the President and CEO of Sanofi-Aventis US (Gregory Irace), on the big changes they are undergoing to re-structure the company, and the way they deliver information.

Coming up next month:

DigitalPharma

Oct. 19-21 - eXL’s Digital Pharma conference, Bridgewater, NJ. This event will be quite progressive, with more of an informal “unconference” format to maximize interaction. I’ll be co-leading a pre-conference workshop on the 19th on social media, and live-blogging/Twittering. Here’s a discount code for 15% your registration: P615WOO

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

We’ll be giving live updates of the PharmaMed conference from Princeton on Sept. 23 and 24th – but also, you can get a live stream (using CoverItLive) of all the tweets coming from various social media users at the conference (and interacting from outside the conference using the #PharmaMed hashtag) on Twitter.

Launch the CoverItLive window: Click Here

———-

Twitter: @swoodruff

Connect with Steve Woodruff

Read Full Post »

Older Posts »

Follow

Get every new post delivered to your Inbox.

Join 29 other followers